BioSpace News Archive

Deals

Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought

Despite a sharp downturn in initial public offering activity, New York-based gene therapy company Lexeo Therapeutics and French biotech Abivax are seeking funding for their lead candidate programs.

October 2, 2023
·
2 min read
·
Tristan Manalac
Policy

Federal Judge Denies Request to Block Medicare Drug Price Negotiation Program

Judge Michael Newman of the Southern District of Ohio issued a ruling Friday denying the U.S. Chamber of Commerce’s request for a preliminary injunction against the Inflation Reduction Act provisions.

October 2, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Structure Therapeutics’ Weight Loss Candidate Gets Phase I Win, Stock Soars

Shares of the biotech startup jumped as much as 70% on Friday after the company reported promising early-stage results for a four-week trial that included only 24 patients.

October 2, 2023
·
2 min read
·
Connor Lynch
Policy

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.

October 2, 2023
·
2 min read
·
Tristan Manalac
Biotech Bay

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Soleno Therapeutics, Inc. announced the closing of the underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares.

October 2, 2023
·
3 min read
Disposition of Common Shares of Small Pharma Inc.

Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proceeds of $284,199.177.

October 2, 2023
·
1 min read
Biotech Beach

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 02, 2023

Zentalis® Pharmaceuticals, Inc. announced that on October 2, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 101,375 shares of the Company’s common stock to four newly hired employees.

October 2, 2023
·
2 min read
Business

Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release

Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange.

October 2, 2023
·
2 min read
Galderma announces progress with RelabotulinumtoxinA regulatory submissions

Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”).

October 2, 2023
·
3 min read
Pharm Country

Biohaven Announces Proposed Public Offering of Common Shares - October 02, 2023

Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced that it has commenced an underwritten public offering of $200 million of its common shares.

October 2, 2023
·
3 min read